Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) has been associated with the metabolic syndrome. However, it is not clear whether insulin resistance is an independent feature of NAFLD, and it remains to be determined which of the in vivo actions of insulin are impaired in this condition.Methods We performed a two-step (1.5 and 6 pmol min(-1) kg(-1)) euglycaemic insulin clamp coupled with tracer infusion ([6,6-2H2]glucose and [2H5]glycerol) and indirect calorimetry in 12 non-obese, normolipidaemic, normotensive, non-diabetic patients with biopsy-proven NAFLD and six control subjects.Results In NAFLD patients, endogenous glucose production (basal and during the clamp) was normal; however, peripheral glucose disposal was markedly decreased (by 30% and 45% at the low and high insulin doses, respectively, p<0.0001) at higher plasma insulin levels (p=0.05), due to impaired glucose oxidation (p=0.003) and glycogen synthesis (p<0.001). Compared with control subjects, glycerol appearance and lipid oxidation were significantly increased in NAFLD patients in the basal state, and were suppressed by insulin to a lesser extent (p<0.05-0.001). The lag phase of the in vitro copper-catalysed peroxidation of LDL particles was significantly shorter in the patients than in the control subjects (48+/-12 vs 63+/-13 min, p<0.04). Lipid oxidation was significantly related to endogenous glucose production, glucose disposal, the degree of hepatic steatosis, and LDL oxidisability.Conclusions/interpretation Insulin resistance appears to be an intrinsic defect in NAFLD, with the metabolic pattern observed indicating that adipose tissue is an important site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, many studies have shown an increase in fatty acid oxidation and β-hydroxybutyrate in individuals with MASH compared to those without liver steatosis.,38,39 likely driven by the high fatty acid flux to the liver due to Adipo-IR.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535
Self-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Self-citation
Cited by
Items 401–500 of 790
Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing?
Mitsala, A., Tsalikidis, C., Romanidis, Κ., & Pitiakoudis, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29070356 · Cited by 23
Torres, L., Schuch, A., Longo, L., Valentini, B. B., Galvão, G. S., Luchese, E., Pinzon, C., Bartels, R., & Álvares‐da‐Silva, M. R. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100774 · Cited by 24
β-hydroxybutyrate: A crucial therapeutic target for diverse liver diseases
Li, K., Wang, W., Jia-bin, W., & Xiao, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115191 · Cited by 24
Ding, Y., Deng, Q., Yang, M., Niu, H., Wang, Z., & Xia, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s431251 · Cited by 25
Shi, Y., Pizzini, J. D., Wang, H., Das, F., Azees, P. A. A., Choudhury, G. G., Barnes, J. L., Zang, M., Weintraub, S. T., Yeh, C., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00651.2020 · Cited by 26
Chang, P.-F., Lin, Y.-C., Liu, K., Yeh, S.-J., & Ni, Y. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.46 · Cited by 23
Jiang, B., Chen, Y., Zhou, K., Zheng, Y., Chen, Y., Qin, L., Zhu, C., Xia, F., Gu, T., Guo, Y., et al. (2019) · Obesity · doi:10.1002/oby.22432 · Cited by 22
Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2023) · Metabolites · doi:10.3390/metabo13060757 · Cited by 24
Liu, C., Li, N., Sheng, D., Shao, Y., Qiu, L., Shen, C., & Liu, Z. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02100-5 · Cited by 22
Manti, S., Romano, C., Chirico, V., Filippelli, M., Cuppari, C., Loddo, I., Salpietro, C. D., & Arrigo, T. (2014) · Hepatitis Monthly · doi:10.5812/hepatmon.17641 · Cited by 22
Luu, C., Thapa, R., Rose, T. A., Woo, K., Jeong, D. K., Thomas, K., Chen, D., Friedman, M., Malafa, M. P., & Hodul, P. J. (2018) · International Journal of Surgery · doi:10.1016/j.ijsu.2018.09.002 · Cited by 22
Martinelli, I., Bonaventura, M. V. M. D., Moruzzi, M., Amantini, C., Maggi, F., Gabrielli, M. G., Fruganti, A., Marchegiani, A., Dini, F., Marini, C., et al. (2020) · Nutrients · doi:10.3390/nu12051308 · Cited by 22
Usefulness of GPT for Diagnosis of Metabolic Syndrome in Obese Japanese Children
Abe, Y., Kikuchi, T., Nagasaki, K., Hiura, M., Tanaka, Y., Ogawa, Y., & Uchiyama, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1933 · Cited by 22
Sabirin, F., Lim, S. M., Neoh, C. F., & Ramasamy, K. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.844374 · Cited by 22
Liu, H., Xing, Y., Nie, Q., Li, Z., Meng, C., & Ma, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s420872 · Cited by 24
Zhang, R., Cheng, K., Xu, S., Li, S., Zhou, Y., Zhou, S., Kong, R., Li, L., Li, J., Feng, J., et al. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/8491742 · Cited by 21
Hayakawa, J., Wang, M., Wang, C., Han, R. H., Jiang, Z. Y., & Han, X. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.01.002 · Cited by 21
Kim, H. Y., Baik, S. J., Lee, H. A., Lee, B. K., Lee, H. S., Kim, T. H., & Yoo, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-74659-9 · Cited by 21
Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease
Cortez‐Pinto, H., & Machado, M. V. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.2.217 · Cited by 22
Plauth, M., Schütz, T., Pirlich, M., Canbay, A. E., & Arends, J. (2014) · Aktuelle Ernährungsmedizin · doi:10.1055/s-0033-1360016 · Cited by 23
Fructose threshold for inducing organ damage in a rat model of nonalcoholic fatty liver disease
Fakhoury-Sayegh, N., Trak-Smayra, V. E., Sayegh, R., Haidar, F., Obeid, O., Asmar, S., & Khazzaka, A. (2018) · Nutrition Research · doi:10.1016/j.nutres.2018.11.003 · Cited by 21
Wang, X., & Cao, Y. (2025) · Biomolecules · doi:10.3390/biom15020188 · Cited by 24
Insulin resistance in adipose tissue and metabolic diseases
Imi, Y., Ogawa, W., & Hosooka, T. (2022) · Diabetology International · doi:10.1007/s13340-022-00616-8 · Cited by 23
Bedi, O., Aggarwal, S., Trehanpati, N., Ramakrishna, G., Grewal, A. S., & Krishan, P. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01919-w · Cited by 20
Ogorodnikova, A. D., Khan, U. I., McGinn, A. P., Zeb, I., Budoff, M. J., Harman, S. M., Miller, V. M., Brinton, E. A., Manson, J. E., Hodis, H. N., et al. (2013) · Obesity · doi:10.1002/oby.20200 · Cited by 20
Wang, T., Zuo, G., Yao, L., Yuan, C., Li, H., Lai, Y., Chen, Z., Zhang, J., Jin, Y., Yamahara, J., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10901 · Cited by 19
Xu, W., Zhou, F., Zhu, Q., Bai, M., Luo, T., Zhou, L., & Deng, R. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174988 · Cited by 20
New treatments for nonalcoholic fatty liver disease
Harrison, S. A. (2006) · Current Gastroenterology Reports · doi:10.1007/s11894-006-0060-2 · Cited by 20
Forouzesh, P., Kheirouri, S., & Alizadeh, M. (2025) · Scientific Reports · doi:10.1038/s41598-024-73132-1 · Cited by 18
Abdi, A. D., Olvera-Hernández, S., Reyes‐Castro, L. A., Mezo‐González, C. E., Croyal, M., García‐Santillán, J. A., Ouguerram, K., Zambrano, E., & Bolaños, F. J. (2021) · Nutrients · doi:10.3390/nu13093075 · Cited by 18
White adipose tissue in metabolic associated fatty liver disease
Zhu, X., Zeng, C., & Yu, B. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102336 · Cited by 18
Alanine-aminotransferase: an early marker for insulin resistance?
Salazar, M. R., Carbajal, H. A., Curciarello, J. O., Aizpurúa, M., Adrover, R., & Riondet, B. (2007) · PubMed · Cited by 21
Lu, J., Fang, B., Huang, Y., Tao, S., Sun, B., Guan, S., & Jin, Y. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.007 · Cited by 20
Oral glucose effectiveness and metabolic risk in obese children and adolescents
Spreghini, N., Cianfarani, S., Spreghini, M. R., Brufani, C., Morino, G. S., Inzaghi, E., Convertino, A., Fintini, D., & Manco, M. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01303-y · Cited by 18
Nonalcoholic steatohepatitis and insulin resistance in children
Arata, M., Nakajima, J., Nishimata, S., Nagata, T., & Kawashima, H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.917 · Cited by 18
Erratum: miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
Rodrigues, P. M., Afonso, M. B., Simão, A. L., Carvalho, C., Trindade, A., Duarte, A., Borralho, P. M., Machado, M. V., Cortez‐Pinto, H., Rodrigues, C. M. P., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.246 · Cited by 18
Hou, M., Gu, Q., Cui, J., Dou, Y., Huang, X., Li, J., Qiao, L., & Nan, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003141 · Cited by 19
The effect of Ramadan fasting on non-alcoholic fatty liver disease (NAFLD) patients
Arabi, S. M., Zarifi, S. H., Nematy, M., & Safarian, M. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.22038/jfh.2015.4621 · Cited by 17
Wooten, J. S., Nick, T. N., Seija, A., Poole, K. E., & Stout, K. B. (2016) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2016.09.001 · Cited by 18
Mungamuri, S. K., Sinha, S. N., & Javvadi, Y. (2020) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2020035839 · Cited by 19
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
Bril, F., McPhaul, M. J., Kalavalapalli, S., Lomonaco, R., Barb, D., Gray, M. E., Shiffman, D., Rowland, C. M., & Cusi, K. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab417 · Cited by 17
Koo, D.-J., Lee, M. Y., Jung, I., Moon, S. J., Kwon, H., Park, S. E., Rhee, E., & Lee, W. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1110 · Cited by 18
Pathogenesis of Nonalcoholic Fatty Liver Disease
Machado, M. V., & Diehl, A. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00025-2 · Cited by 21
Steatosis in South African women: How much and why?
Naran, N. H., Haagensen, M., & Crowther, N. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191388 · Cited by 17
Mechanisms for increased risk of diabetes in chronic liver diseases
Svegliati‐Baroni, G., Gaggini, M., Carli, F., Barbieri, C., Cucco, M., Younes, R., Rosso, C., Bugianesi, E., & Gastaldelli, A. (2020) · Liver International · doi:10.1111/liv.14556 · Cited by 17
Self-citationHurjui, D. M., Niță, O., Graur, L. I., Mihalache, L., Popescu, D. Ş., Huţanaşu, I. C., Ungureanu, D. A., & Graur, M. (2012) · The Medical-Surgical Journal · Cited by 17
Rabbani, N., & Thornalley, P. J. (2025) · Clinical Science · doi:10.1042/cs20257727 · Cited by 17
Furukawa, Y., Tamura, Y., Takeno, K., Funayama, T., Kaga, H., Suzuki, R., Watanabe, T., Kakehi, S., Kanazawa, A., Kawamori, R., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12731 · Cited by 17
Insulin resistance and the role of gamma-aminobutyric acid
Rezazadeh, H., Sharifi, M., & Soltani, N. (2021) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_374_20 · Cited by 17
Omelchenko, E., Gavish, D., & Shargorodsky, M. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.03.002 · Cited by 16
Simon, T. G., Corey, K. E., Chung, R. T., & Giugliano, R. P. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4330-z · Cited by 17
La steatosi epatica non alcolica: una nuova insidia per il cardiologo
Tarquini, R., Lazzeri, C., Boddi, M., Marra, F., Abbate, R., & Gensini, G. F. (2010) · Giornale italiano di cardiologia · doi:10.1714/562.6676 · Cited by 21
Tura, A., Pacini, G., Winhofer, Y., Bozkurt, L., Di Benedetto, G., Morbiducci, U., Roden, M., & Kautzky‐Willer, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03477.x · Cited by 15
Rashidmayvan, M., Vandyousefi, S., Barati, M., Salamat, S., Ghodrat, S., Khorasanchi, M., Jahan-Mihan, A., Nattagh‐Eshtivani, E., & Mohammadshahi, M. (2022) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2022.101598 · Cited by 15
Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway
Tong, J., Cong, L., Jia, Y., He, A. B.-L., Guo, Y., He, J., Li, D., Zou, B., & Li, J. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s380053 · Cited by 17
Lee, S., Bae, J., Jo, D. R., Lee, M., Lee, Y., Kang, E. S., Soo, B., & Lee, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1124576 · Cited by 15
Lee, G. H., Phyo, W. W., Loo, W. M., Kwok, R., Ahmed, T., Shabbir, A., So, J. B. Y., Koh, C. J., Hartono, J. L., Muthiah, M. D., et al. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i12.1228 · Cited by 15
Kastberg, S. E., Lund, H. S., Rolfe, E. D. L., Kaduka, L. U., Boit, M. K., Corpeleijn, E., Friis, H., Bernard, S., Paquette, M., Baass, A. W., et al. (2021) · Tropical Medicine & International Health · doi:10.1111/tmi.13696 · Cited by 15
Lundsgaard, A., Bojsen-Møller, K. N., & Kiens, B. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.08.005 · Cited by 15
Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
Bae, J., & Lee, B. (2023) · Biomolecules · doi:10.3390/biom13101506 · Cited by 15
Wu, Y. S., Lin, Y., Yang, W., Wang, S., & Chen, Y. (2021) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3351 · Cited by 16
Oxidative Stress in Nonalcoholic Fatty Liver Disease
Marí, M., Morales, A., Colell, A., García‐Ruiz, C., & Fernández-Checa, J. C. (2015) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-15539-5_12 · Cited by 16
Activin A in Nonalcoholic Fatty Liver Disease
Yndestad, A., Haukeland, J. W., Dahl, T. B., Halvorsen, B. L., & Aukrust, P. (2011) · Vitamins and hormones · doi:10.1016/b978-0-12-385961-7.00015-9 · Cited by 15
Arterial hypertension, obesity and non-alcoholic fatty liver disease: is there any connection?
Kuzmіnova, N. V., Gribenyuk, O. V., Osovska, N. Y., & Knyazkova, І. І. (2016) · Arterial Hypertension · doi:10.5603/ah.2016.0025 · Cited by 15
Ding, X., Xu, Y., Wang, Y., Li, X., Lu, C., Su, J., Ma, Y., Chen, Y., Yin, Y., Zhang, L., et al. (2017) · International Journal of Endocrinology · doi:10.1155/2017/5262560 · Cited by 14
Hong, S., Lee, J. S., Kim, J. A., Lee, Y., Roh, E., Yu, J. H., Kim, N. H., Yoo, H. J., Seo, J. A., Kim, S. G., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108922 · Cited by 16
Liver function as an engineering system
Ashworth, W., Pérez-Galván, C., Davies, N. A., & Bogle, I. D. L. (2016) · AIChE Journal · doi:10.1002/aic.15292 · Cited by 14
Jeon, D., Park, B. H., Lee, H. C., Park, Y., Lee, W., Lee, J. H., Song, K. B., Hwang, D. W., Kim, S. C., & Choi, J. (2022) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1150 · Cited by 13
Lim, T. S., Chun, H. S., Kim, S. S., Kim, J. K., Lee, M., Cho, H. J., Kim, S. U., & Cheong, J. Y. (2023) · Gut and Liver · doi:10.5009/gnl220400 · Cited by 13
Management and diagnosis of fatty liver disease
Schneier, A., Citti, C., & Dieterich, D. T. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1003209 · Cited by 15
Non-alcoholic fatty liver disease in the patients presenting with abdominal obesity
Livzan, M. A., Korolevets, T. S., Lapteva, I., & Александровна, Ч. Н. (2014) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro2014348-14 · Cited by 13
The Role of Oxidative Inactivation of Phosphatase PTEN and TCPTP in Fatty Liver Disease
Huu, T. N., Park, J., Zhang, Y., Thanh, H. D., Park, I., Choi, J. M., Yoon, H. J., Park, S. C., Woo, H. A., & Lee, S.-R. (2023) · Antioxidants · doi:10.3390/antiox12010120 · Cited by 15
Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease
Melis, M., Tang, X., Trasino, S. E., Patel, V. M., Stummer, D. J., Jessurun, J., & Gudas, L. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211071 · Cited by 13
Valtueña, S., Numeroso, F., Ardigò, D., Pedrazzoni, M., Franzini, L., Piatti, P. M., Monti, L. D., & Zavaroni, I. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01960 · Cited by 15
Koška, J., Ortega, E., Bogardus, C., Krakoff, J. A., & Bunt, J. C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00662.2006 · Cited by 16
Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2132145 · Cited by 12
“opment in obesity and progression of NAFLD [38,39].”
BackgroundZhang, L., Gao, S., Luan, Y., Su, S., Zhang, E., Liu, J., Xie, S., Zhang, Y., Yue, W., Liu, R., et al. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.104943 · Cited by 12
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 12
Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 12
Self-citationEvaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
Abeysekera, K. W. M., Orr, J. G., Gordon, F. H., Howe, L. D., Hamilton-Shield, J. P., Heron, J., & Hickman, M. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02401-y · Cited by 12
Tao, X., Chen, C., Huang, Z., Yu, L., Wang, M.-R., Wang, S., & Tian, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05792-2 · Cited by 12
Thapa, K., Grewal, A. S., Kanojia, N., Rani, L., Sharma, N., & Singh, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200121143959 · Cited by 14
Non-alcoholic fatty liver disease in non-obese children
Zdanowicz, K., Białokoz‐Kalinowska, I., & Lebensztejn, D. M. (2020) · Hong Kong Medical Journal · doi:10.12809/hkmj198361 · Cited by 12
Efficacy of Tiopronin in treatment of severe non-alcoholic fatty liver disease.
Mc, T., Cheng, L., Qiu, L., Rg, J., Sun, R.-Q., Xp, W., Gy, H., & Zhao, Y. (2014) · PubMed · Cited by 12
Sandby, K., Krarup, T., Chabanova, E., Geiker, N. R. W., & Magkos, F. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae572 · Cited by 11
Dorostghol, M., Gharibvand, M. M., Hanafi, M. G., & Motamedfar, A. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_94_23 · Cited by 11
Liu, Z., Hu, Y., Yang, X., Tan, A., Gao, Y., Qin, X. Y., Liang, Y., Mo, Z., & Peng, T. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.08.022 · Cited by 11
Diastolic dysfunction and cardiovascular risk in old subjects: Possible association with NAFLD?
Gianotti, G., Cenni, A., Bianchi, G. P., Masetti, M., Zappoli, P., Muscari, A., & Zoli, M. (2013) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2013.10.012 · Cited by 11
The color of fat and its central role in the development and progression of metabolic diseases
Gaggini, M., Carli, F., & Gastaldelli, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0060 · Cited by 12
Self-citationWang, B., Li, F., Guo, J., Wang, C., Xu, D., & Li, C. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.7043 · Cited by 12
Singal, P., Muniyappa, R., Chisholm, R., Hall, G., Chen, H., Quon, M. J., & Mather, K. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00603.2009 · Cited by 11
[Pathophysiology of non-alcoholic steatohepatitis. An insulin resistance overview].
Macías‐Rodríguez, R. U., & Torre, A. (2009) · PubMed · Cited by 13
Yang, D., Lan, J., Cen, J., Han, Y. Y., & Hu, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s396011 · Cited by 10
Ruan, S., Yuan, X., Liu, J., Zhang, Q., & Ye, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s441641 · Cited by 10
Associations between subcutaneous adipocyte hypertrophy and nonalcoholic fatty liver disease
Holmer, M., Hagström, H., Chen, P., Danielsson, O., Aouadi, M., Rydén, M., & Stal, P. I. (2022) · Scientific Reports · doi:10.1038/s41598-022-24482-1 · Cited by 10
Yoo, T., Choi, W., Hong, J.-H., Lee, J., Kim, J., Shin, I., Yang, S. J., Amminger, G. P., Berk, M., Yoon, J., et al. (2018) · Psychiatry Investigation · doi:10.30773/pi.2017.08.30 · Cited by 11
Mohammed, I., & Kakey, E. (2020) · Al-mağallaẗ al-ʻirāqiyyaẗ li-l-ʻulūm al-bayṭariyyaẗ/Iraqi journal of veterinary sciences · doi:10.33899/ijvs.2019.125574.1089 · Cited by 10
Gunn, P. J., Pramfalk, C., Millar, V., Cornfield, T., Hutchinson, M., Johnson, E. M., Nagarajan, S. R., Troncoso‐Rey, P., Mithen, R. F., Pinnick, K. E., et al. (2020) · Physiological Reports · doi:10.14814/phy2.14482 · Cited by 12
Oriquat, G. A. (2018) · Meta Gene · doi:10.1016/j.mgene.2018.08.008 · Cited by 11
Liu, J., Li, F., Zeng, Q., Hu, W., Yang, L., Luo, S., Li, D., & Deng, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1669805 · Cited by 14
Metadata
- Authors
- Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M.
- Affiliations
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Pisa (IT)
- Corresponding author
- Bugianesi, E.
- Venue
- Diabetologia
- Published
- 2005-03-04
- Volume
- 48
- Issue
- 4
- Pages
- 634-642
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1975388439
- Cited by
- 770
- References
- 63
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 42 · 2023: 48 · 2022: 47 · 2021: 48 · 2020: 51 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 49 · 2015: 37 · 2014: 40 · 2013: 35 · 2012: 32
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, insulin resistance, glucose oxidation, hepatic glycogen synthesis, lipid oxidation, hepatic steatosis, adipose tissue, non-diabetic patients
- MeSH terms
- Adipose Tissue, Adult, Blood Glucose, Body Composition, C-Peptide, Calorimetry, Indirect, Enzymes, Fasting, Fatty Acids, Nonesterified, Fatty Liver, Glucose, Glycerol, Humans, Insulin, Insulin Resistance, Lipids, Lipoproteins, LDL, Liver, Male, Middle Aged, Oxidation-Reduction, Glucose Clamp Technique, 3-Hydroxybutyric Acid, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.